<DOC>
	<DOCNO>NCT03059953</DOCNO>
	<brief_summary>For patient moderate plaque psoriasis intolerable , contraindication fail classical systemic treatment , current commonly employed management strategy encompass treatment biologic agent . The direct indirect cost biologic treatment , accrue , among others , high drug acquisition administration cost , require baseline safety screen subsequent routine monitoring well potential loss patient ' work hour constitute significant financial burden public healthcare system . In light evidence , appear routine care apremilast may fulfill important gap treatment armamentarium psoriasis provide promising treatment option employ prior biologics , demonstrate efficacy even hard-to-treat area scalp , nail , palm sol , limit manageable safety profile , convenient cost-effective biologics . In view scarcity real-world evidence regard impact apremilast patient ' health-related quality life ( HRQoL ) extent severity disease , consideration moderate psoriasis patient { define [ 10 &lt; body surface area ( BSA ) &lt; 20 10 &lt; psoriasis area severity index ( PASI ) &lt; 20 ] 10 &lt; dermatology quality life index ( DLQI ) &lt; 20 } , naïve biologic treatment likely underrepresented pivotal ESTEEM trial since approximately 30 % enrolled patient previously treat biologic therapy , 28-30 % baseline PASI score &gt; 20 , 48-52 % BSA &gt; 20 % , study represent attempt examine impact apremilast routine clinical practice setting Greece patient moderate plaque psoriasis therapeutic strategy precedes biologics treatment algorithm . Specifically , present study aim generate novel real-world evidence effect apremilast treatment biologic treatment naïve patient moderate plaque psoriasis term patient ' HRQoL , patient-perceived benefit therapy , treatment response rate , impact nail , scalp palmoplantar psoriatic involvement severity pruritus , concurrently assess apremilast survival rate cost per PASI-75 responder routine clinical practice Greece .</brief_summary>
	<brief_title>A Study Treatment With APRemilast Moderate psoriAsIS Real Life clinicAL Practice ( The 'APRAISAL ' Study )</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Apremilast</mesh_term>
	<criteria>Patients eligible inclusion study meet follow criterion : Male female patient ≥ 18 year age time informed consent ; Patients diagnose moderate chronic plaque psoriasis [ ( 10 &lt; BSA &lt; 20 10 &lt; PASI &lt; 20 ) 10 &lt; DLQI &lt; 20 ] , fail respond contraindication , intolerant classical systemic therapy ; Patients naïve biologic treatment ; Patients decision prescribe therapy apremilast ( Otezla® ) accord locally approve summary product characteristic ( SmPC ) already take prior enrollment study clearly separate physician 's decision include patient current study ; Patients available BSA , PASI DLQI score start apremilast treatment ; Patients must able read , understand complete study specific questionnaire ; Patients must provide write Informed Consent prior inclusion study ; Patients must able adhere study visit schedule protocol requirement . A patient meet follow criterion exclude participation study : Patients initiated treatment apremilast 7 day enrollment study ; Patients meet contraindication administration apremilast outline late version locally approve SmPC ; Patients currently receive treatment investigational drug/device/intervention receive investigational product within 30 day 5 halflives investigational agent ( whichever longer ) commencement therapy apremilast ; Patients currently pregnant , breastfeed , plan pregnancy study observation period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>